Home » General World News » Drug giant Novartis is going after a $5 billion eye-drug market (NVS)

Drug giant Novartis is going after a $5 billion eye-drug market (NVS)





Novartis incoming CEO Vas Narasimhan
  • Novartis on Friday showed that its drug, brolucizumab, worked as well as an existing drug that’s used to treat age-related macular degeneration.
  • It’s a condition that affects more than 2 million people in the US.
  • The hope is to get the drug approved to take on a roughly $5 billion market.

Novartis is gearing up to shake up a huge eye-drug market.

In data presented Friday at the American Academy of Opthamology annual conference, Novartis’ drug brolucizumab showed that it wasn’t any worse than Eylea, an existing drug to treat a condition called age-related macular degeneration. Novartis’ drug was read more >>>

Source:: BusinessInsider.Com

Comments are closed.